This excerpt from the Q1 2022 report by Deep Pharma Intelligence highlights how Genomenon’s AI-driven approach identified 3.7x more evidence-supported, pathogenic/likely pathogenic variants.
We help provide insights into key genetic drivers of diseases and relevant biomarkers. By working together to understand this data, we enable scientists and researchers to make more informed decisions on programs of interest. To learn more about how we can partner together to find your genomic variant solutions, we invite you to click on the link below.